Taiwan · Delayed Price · Currency is TWD BioGend Therapeutics Statistics
Total Valuation
TPEX:6733 has a market cap or net worth of TWD 2.74 billion. The enterprise value is 1.93 billion.
| Market Cap | 2.74B |
| Enterprise Value | 1.93B |
Important Dates
The next estimated earnings date is Friday, February 26, 2027.
| Earnings Date | Feb 26, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6733 has 134.32 million shares outstanding. The number of shares has increased by 2.97% in one year.
| Current Share Class | 134.32M |
| Shares Outstanding | 134.32M |
| Shares Change (YoY) | +2.97% |
| Shares Change (QoQ) | -0.56% |
| Owned by Insiders (%) | 3.97% |
| Owned by Institutions (%) | 2.30% |
| Float | 77.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.65 |
| PB Ratio | 2.62 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.30, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.30 |
| Quick Ratio | 10.59 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -867.83 |
Financial Efficiency
Return on equity (ROE) is -9.91% and return on invested capital (ROIC) is -7.34%.
| Return on Equity (ROE) | -9.91% |
| Return on Assets (ROA) | -6.80% |
| Return on Invested Capital (ROIC) | -7.34% |
| Return on Capital Employed (ROCE) | -10.13% |
| Weighted Average Cost of Capital (WACC) | 4.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 27 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 2.67 |
Taxes
| Income Tax | -8.31M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.49% in the last 52 weeks. The beta is 0.13, so TPEX:6733's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -47.49% |
| 50-Day Moving Average | 24.27 |
| 200-Day Moving Average | 28.45 |
| Relative Strength Index (RSI) | 20.01 |
| Average Volume (20 Days) | 70,443 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TPEX:6733 had revenue of TWD 235.24 million and -83.22 million in losses. Loss per share was -0.66.
| Revenue | 235.24M |
| Gross Profit | 170.37M |
| Operating Income | -108.48M |
| Pretax Income | -99.35M |
| Net Income | -83.22M |
| EBITDA | -61.09M |
| EBIT | -108.48M |
| Loss Per Share | -0.66 |
Balance Sheet
The company has 824.40 million in cash and 3.83 million in debt, with a net cash position of 820.56 million or 6.11 per share.
| Cash & Cash Equivalents | 824.40M |
| Total Debt | 3.83M |
| Net Cash | 820.56M |
| Net Cash Per Share | 6.11 |
| Equity (Book Value) | 1.06B |
| Book Value Per Share | 8.00 |
| Working Capital | 872.21M |
Cash Flow
In the last 12 months, operating cash flow was -59.34 million and capital expenditures -3.09 million, giving a free cash flow of -62.43 million.
| Operating Cash Flow | -59.34M |
| Capital Expenditures | -3.09M |
| Depreciation & Amortization | 47.39M |
| Net Borrowing | -3.74M |
| Free Cash Flow | -62.43M |
| FCF Per Share | -0.46 |
Margins
Gross margin is 72.42%, with operating and profit margins of -46.11% and -35.38%.
| Gross Margin | 72.42% |
| Operating Margin | -46.11% |
| Pretax Margin | -42.23% |
| Profit Margin | -35.38% |
| EBITDA Margin | -25.97% |
| EBIT Margin | -46.11% |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6733 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.97% |
| Shareholder Yield | -2.97% |
| Earnings Yield | -3.23% |
| FCF Yield | -2.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TPEX:6733 has an Altman Z-Score of 25.33 and a Piotroski F-Score of 1.
| Altman Z-Score | 25.33 |
| Piotroski F-Score | 1 |